Group 1 - The core viewpoint of the news is that the market's reaction to the pre-sale performance of Giant Bio during the live broadcast by influencer Li Jiaqi is considered excessive, as the company's promotional strategy has made its products less price-attractive compared to competitors [1][2] - Giant Bio's stock price has seen significant volatility, with a drop of over 15% recently and reaching a new low of 40.6 HKD, reflecting investor concerns about its sales performance [1] - Citigroup's report indicates that the company's revenue growth is expected to be 16% year-on-year in the second half of the year, despite a projected decline of 10% on Tmall [2] Group 2 - Citigroup predicts that Giant Bio's sales will recover in the fiscal year 2026, with a high growth rate of 19% due to a low base and no negative customer feedback [2] - The target price for Giant Bio's stock has been adjusted from 69.4 HKD to 55.4 HKD based on a 20 times price-to-earnings ratio for the fiscal year 2026, while maintaining a "buy" rating [2] - The performance of KOL live broadcasts is noted to be declining, impacting the company's sales, with expectations of a 25% increase on Douyin and a 100% increase on JD, while offline sales are expected to grow by 10% [2]

Core Viewpoint - The stock of Giant Bio (02367) has experienced significant volatility, with a recent drop of nearly 3% after a previous decline of over 15%, reaching a new low of 40.6 HKD, attributed to market reactions to its pre-sale performance during a major live-streaming event [1] Group 1: Stock Performance - Giant Bio's stock opened high but fell sharply, with a midday drop of nearly 3%, and a previous day decline exceeding 15% [1] - The stock price hit a new low of 40.6 HKD, marking the lowest point in over a year [1] - As of the latest update, the stock was down 2.92%, with a trading volume of 678 million HKD [1] Group 2: Market Analysis - Citigroup's report indicates that the market's reaction to Giant Bio's pre-sale performance during the live-streaming event with influencer Li Jiaqi was excessive [1] - The report highlights that Giant Bio's main products were less price-competitive due to stricter promotional strategies compared to other brands [1] - Citigroup predicts a relatively weak performance for Giant Bio in Q3 and the first two weeks of October, primarily due to fewer KOL live-streaming events [1] Group 3: Revenue Forecast - Citigroup forecasts a 16% year-on-year revenue growth for Giant Bio in the second half of the year, with specific expectations of a 10% decline on Tmall, a 25% increase on Douyin, a 100% growth on JD, and a 10% increase in offline sales [1] - For the fiscal year 2026, Citigroup anticipates a continuation of high growth at 19% due to a low base and no negative customer feedback [1] - The target price for Giant Bio has been adjusted from 69.4 HKD to 55.4 HKD based on a 20x price-to-earnings ratio for the fiscal year 2026, while maintaining a "buy" rating despite lowering profit forecasts [1]